About this event
- Date and time Wed 18 Jan 2023 from 9:00am to 4:30pm
- Location Royal Society of Medicine
- Organised by Digital Health
Digital therapeutics (DTx) have been evolving for over a decade and promise to supplement or potentially replace some clinical therapies. Their potential value in facilitating significant benefits, such as meeting unmet patient needs, self-management of chronic conditions by patients, delivering treatment more affordably, reducing demands on clinician's time or being a non-pharmacological treatment.
Join this in-person event that will provide an up-to-date understanding of digital therapeutics and the opportunities to improve patient experience and outcomes, whilst delivering value for healthcare and supporting clinicians in providing care more effectively, safely and efficiently. It will also examine the regulatory landscape from the regulators and the experiences of innovators bringing solutions to the market, the latest designs, developments and deployment, and the potential influence and opportunities of DTx in their field of work.
During this event, you will:
- Understand the concept of digital therapeutics and fields in which technologies are emerging
- Learn from case studies of DTx use, the potential adaption of patient pathways and benefits to workflow
- Develop insight into DTx requirements, evidence base, regulation and reimbursement
- Learn how to consider the patient safety aspect of digital therapeutics
Follow us on:
Facebook
Instagram
LinkedIn
Twitter
YouTube
We would like to thank our sponsoring partner TTP for their support of this meeting.
Agenda
View the programme
Registration, tea and coffee
Welcome and introduction
Ms Julia Manning, President-Elect, Digital Health Section, Royal Society of Medicine
Keynote presentation
Overview of digital therapeutics
Dr Hugh Harvey, Hardian Healthcare
Session 1: Can digital therapeutics contribute to NHS improvement?
Chair: Ms Julia Manning, President-Elect, Digital Health Section, Royal Society of Medicine
Understanding NHS needs inside and out
Dr Harpreet Sood, Vice-President, Huma Healthcare Company
Thoughts of a chief nurse
Professor Sultan Mahmud, Director of Healthcare, BT Group PLC
Virtual care expanded to other populations: How to make it accessible?
Mr Tony Bowden, Chief Executive Officer, Helicon Health
Tea and coffee break
Session 2: Digital therapeutics case studies
Chair: Dr Tim Ringrose, President, Digital Health Section, Royal Society of Medicine
Pathway through pain
Dr John O'Dowd, Consultant Spinal Surgeon
Parkinsons kinetigraph
Professor Camille Carroll, Clinical Neuroscience Professor, University of Plymouth, Honorary Consultant Neurologist, University Hospitals Plymouth NHS Trust
Artificial pancreas: Cam APS
Ms Hilary Nathan, Director of Policy and Communications and Community Engagement, UK Juvenile Diabetes Research Foundation
Keynote presentation
Transforming community care
Dr Andy Jones, Global Chief Growth Officer, Ramsay Health Care UK
Lunch break
Keynote presentation
Digital therapeutics for patient choice and support
Ms Liz Ashall-Payne, Chief Executive Office, ORCHA
Session 3: Regulation, investment and reimbursement
Chair: Dr Michelle Tempest, Digital Health Section, Royal Society of Medicine
Evolution of digital therapeutics regulation across
Ms Megan Coder, Chief Policy Officer, Digital Therapeutics Alliance
Practical advice about digital therapeutics
Mr Ifran Hassan, Quality and Regulatory Manager, Psephos Biomedica
Transforming effectiveness and improving outcomes through closed loop models of care
Dr Hakin Yadi, Chief Executive Officer, Closed Loop Medicine
Tea and coffee break
Session 4: Innovation for patients - ensuring engagement
Chair: Mr David Taylor, Digital Health Section, Royal Society of Medicine
Digital therapeutics design and development for patient adherence
Mr Dan Lock, Consultant, The Technology Partnership
The Sleepio Story
Ms Heather Cook, Special Advisory, Big Health
Pharmaceutical view: Clinical trials and engagement
Ms Cristina Duran, Chief Digital Health Officer, Astra Zeneca
Session 5: Digital therapeutics debate: Barriers and facilitators, power and privacy
Chair: Mr Richard Sargeant, Managing Director and Partner, Boston Consulting Group
Ms Liz Ashall-Payne
Mr Richard Sargeant, Managing Director and Partner at Boston Consulting Group
Ms Julia Manning, Teaching Fellow, UCL Interaction Centre, Department of Computer Science, University College London
Professor James Wilson, Professor of Philosophy, University College London
Close of meeting
Drinks reception
Sponsors
Location
Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom
Disclaimers:
Registration for this event will close on 17 January 2023 at 1:00am (BST). Late registrations will not be accepted.
The agenda is subject to change at any time
All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations.
We are only able to share presentations that we have received permission to share. This is at the presenter and the RSM’s discretion.
This event will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.